SU5416 attenuated lipopolysaccharide-induced acute lung injury in mice by modulating properties of vascular endothelial cells

Background and aim: A potent and selective vascular endothelial growth factor receptor (VEGFR) inhibitor SU5416, has been developed for the treatment of solid human tumors. The binding of VEGF to VEGFR plays a crucial role in the pathophysiology of respiratory disorders. However, the impact of SU541...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xuqing, Zhu, Junqi, Jiang, Yuyue, Xu, Changqing, Lv, Qun, Yu, Dongwei, Shi, Kai, Ruan, Zhaoyang, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536715/
https://www.ncbi.nlm.nih.gov/pubmed/31213766
http://dx.doi.org/10.2147/DDDT.S188858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536715/
https://www.ncbi.nlm.nih.gov/pubmed/31213766
http://dx.doi.org/10.2147/DDDT.S188858

Ejemplares similares